Evaluation of computational genotyping of Structural Variations for clinical diagnoses.

Varuna Chander[1], Richard A. Gibbs[1], Fritz J. Sedlazeck[1]*

1: Human Genome Sequencing Center, Baylor College of Medicine, One Baylor Plaza, Houston TX 77030

VC: Varuna.Chander@bcm.edu
RG: agibbs@bcm.edu
FJS: fritz.sedlazeck@bcm.edu
* Correspondence: fritz.sedlazeck@bcm.edu

Abstract

Background:
In recent years, Structural Variation (SV) has been identified as having a pivotal role in causing genetic disease. Nevertheless, the discovery of SVs based on short DNA sequence reads from next-generation DNA sequence methods is still error-prone, suffering from low sensitivity and high false discovery. These shortcomings can be partially overcome with the use of long reads, but the current expense precludes their application for routine clinical diagnostics. Structural Variation genotyping, on the other hand, offers cost-effective application as diagnostic tool in the clinic, with potentially no false positives and low occurrence of false negatives.

Results:
We assess five state- of-the- art SV genotyping software methods that test short read sequence data. These methods are characterized based on their ability to genotype certain SV types and size ranges. Furthermore, we analyze their applicability to parse different VCF file sub-formats, or to rely on specific meta information that is not always at hand. We compare the SV genotyping methods across a range of simulated and real data including SVs that were not found with Illumina data alone. We assess their sensitivity and ability to filter out initial false discovery calls to assess their reliability.

Conclusion:
Our results indicate that, although SV genotypers have superior performance to SV callers, there are performance limitations that suggest the need for further innovation.

Keywords (3-10)
Structural Variations, Genotyping, clinical diagnosis, Next Generation Sequencing

Background
With the continuous advancement of sequencing technologies, our understanding of the importance of Structural Variation (SV) is increasing[1]. Structural Variation has a critical role in evolution[2], genetic diseases (e.g. mendelian or Cancer) [2, 3] and the regulation of genes in different cells and tissues[4]. Furthermore, SVs compromise a substantial proportion of

42 genomic differences between cell types, individuals, populations and species [1, 4-8]. Structural
43 Variation is generally identified as being 50bp or longer genomic variations and categorized into
44 five types: Insertions, Deletions, Duplications, Inversions and Translocations [9]. They are most
45 often identified by leveraging paired-end, split read signals and coverage information[8].
46
Methods for the detection of SVs are still in their infancy, with some procedures reporting high
(up to 89%) levels of false discovery[7, 8, 10-12] (i.e. SVs that are inferred due to artifacts, but
not truly present in the sample) and between 10% to 70% false negatives[5, 7] (i.e. missing
present SVs in the samples). Although the performance of these methods can improve by the
use of long DNA sequence reads, this is often not practical due to high sequencing costs [13-
15]. Therefore, using short reads alone significantly hinders SV discovery for routine clinical
diagnosis [16].
54
An additional challenge is the interpretation of the possible functional consequences of SVs.
Despite the availability of existing methods to compare SVs (e.g. SURVIVOR [5]) and to study
the potential impact of SVs on genes (VCFanno [17], SURVIVOR_ant [18]), there is still a paucity
of methods to assess their allele frequency among the human populations. These issues lead to
problems that hinder routine screening for SVs in patient data and limit their proper
recognition and characterization for clinical diagnoses.
61
The identification of SVs that have been previously identified in different samples is, in
principle, easier than *de novo* detection. For known SVs it is possible to computationally detect
SVs directly from short read DNA sequence data in individual per patient samples, guided by
the expected position of split reads and discordant paired reads that can confirm breakpoints.
This is less demanding than calling *de novo* SVs, since we focus only on specific genomic
regions. This approach reduces the false discovery rates and therefore, reduces the potential
misdiagnosis of patients. In addition, the false negative rate can be reduced as it is easier to
genotype a variant than to identify a new SV. Genotyping known SVs has further the advantage
that previous studies are likely to have annotated the event, and its possible association with
certain diseases. Such events are recorded in SV databases (e.g. dbVar [19]).
72
73 In this paper, we review the current state of SVs genotyping methods and investigate their
74 potential applicability for clinical diagnosis. In particular, we address whether these SV
75 genotypers can re-identify SVs that short read callers were initially blind to (over GiaB [20] call
76 sets) and how they perform for initially falsely inferred SVs. We precisely map out which
77 genotypers operate on which types of SVs and their ability to genotype SVs based on sizes.
78
Analyses
Existing methods
Here we assess SVs genotyping methods: DELLY [21], Genome STRiP [22], STIX[23], SV2 [24] and
SVTyper [25]. They share a common feature in which they require a bam file of the mapped
reads and a VCF file that will be genotyped for SVs as inputs. **Table 1** lists their dependencies
and their ability to genotype certain types of SVs.

Overall, they can be divided into groups that support only two SV types (e.g. Genome STRiP) up
to methods that support all SV types (SVTyper and DELLY), but require specific meta-
information to do so. In the following, we give a brief description of each method that we
assessed. Further insights can be obtained from their respective publications or manuals.
90
91
92
93

Genotyper	Approach	SV Type					Inputs	Dependencies
		Del	Ins	Inv	Dup	Tra		
Delly	RD, PR, SR	☐		☐	☐	☐	BAM, VCF, Ref	Bcftools [26]
Svtyper	SR, PR	☐		☐	☐	☐	BAM, VCF, Ref	
SV2	RD, PR, SR	☐			☐		BAM, SNV VCF, VCF, Ref, PED file	
STIX	PR,SR	☐		☐			BAM compressed, PED file, VCF, Ref	Excord, Giggle [27]
Genome StRiP	RD, PR, SR	☐			☐		BAM, VCF, Ref	GATK[28]

Table 1: Overview of the SV genotypers assessed here and their ability to assess different SV types. RD: read depth, SR: split
reads, PR: paired end reads

DELLY[21] is originally an SV caller that includes a genotype mode to redefine multi-sample
VCFs. It operates on split and paired-end reads to genotype deletions, duplications, inversions
and translations. However, for all types except the deletions, DELLY requires a sequence
resolved call in its own format to be able to estimate the genotype.
100
101 Genome STRiP[22] genotypes only deletions and duplications. The unique aspect of Genome
102 STRiP is that it was designed to genotype multiple samples simultaneously. It requires the GATK
103 pipeline and prepackaged reference metadata bundles.
104
STIX[23], which is the most recently developed method included here, utilizes a reverse
approach to the previous two examples. First, STIX extracts the discordant read pairs and split
reads and generates a searchable index per sample. This index can then be queried if it
supports a particular variant call. Noteworthy, STIX in the current form only provides
information on how many reads support a variant rather than the genotype itself. This is done
with a flag describing whether the reads are supported by a particular variant and the number
of reads supporting it.
112
113 SVTyper[25] uses a Bayesian likelihood model that is based on discordant paired-end reads and
114 split reads. It was designed to genotype deletions, duplications, inversions and translocations.

115 For the latter, however, SVTyper requires specific ID tags provided by Lumpy[29] to complete
116 genotyping.
117
118 SV2[24] uses a support vector machine learning to genotype deletions and duplications based
119 on discordant paired-end, split read and coverage. Furthermore, it was the only SV genotyper
120 assessed here that leverages SNP calls for its prediction.
121
<u>Evaluation of SVs computational genotypers based on simulated data</u>
To first assess the performance of genotyping methods for SVs, we simulated data sets with
100bp Illumina like paired-end reads. Each data set includes 20 SVs simulated for a certain SVs
type (duplications, indels, inversions and translocation) and a certain size range (100bp, 250bp,
500bp, 1kbp, 2kbp, 5kbp, 10kbp, 50kbp). For each of the data sets, we called SVs using
SURVIVOR[5] based on a union set of DELLY, Manta[30], Lumpy[29] calls to include true positive
as well as false positive SVs calls (see methods). Given the nature of the simulated data, we only
observed 17 false discoveries while we were missing 17.25% of the simulated SVs.
Supplementary Table 1 shows the results for the discovery set over the 32 simulated data sets
based on 640 simulated SVs on chr21 and chr22.

The generated VCF files were taken as input for five SV genotyper callers: DELLY, Genome STRiP, SV2, STIX and SVTyper. **Figure 1** provides an overview with respect to the ability to discover SVs in the first place (SURVIVOR). **Supplementary Table 1** shows the result for all genotypers applied to the 32 simulated data sets. Interestingly, we observed that not all methods accept a standardized VCF file and certain SV types require unique information. For example, while SVTyper is able to genotype deletions, inversion and duplications, it will just work on BND (translocation) events if the ID pairs provided by Lumpy are included in the VCF file. Also DELLY, which is also capable to infer deletions, inversion, duplications and translocations types of SVs is only able to genotype deletions given a standardized VCF without the extra information.

The overall performance of each method was evaluated based on the input VCF generated by
SURVIVOR. Thus, if all of the short read based SV callers were not able to resolve the insertions
of 5kbp, then it would count as wrong/missed identified SV. In addition, we assessed the ability
for the SV genotyper to filter out falsely called SVs. SVTyper (64.70%) had the highest rate of
correctly genotyping SVs to be present, followed by SV2 (41.57%). Importantly, SV2 was able to
genotype deletions and duplications, while SVTyper assessed deletions, duplications and
inversions. Genome STRiP had the lowest (13.40%) success rate of all methods because it can
only genotype deletions and duplications. This may reflect that Genome STRiP was designed
primarily for population-based genotyping. SVTyper improved marginally (86.26%) when BND
events, which represented translocations, were ignored, followed by the second best method
SV2 (83.15%) when focused on deletions and duplications.
159
Next, we assessed the ability of the SV genotypers to reduce the false positives, i.e. initially
wrongly inferred SVs. This will represent the scenario of accidentally genotyping a SV that is not
represented in the sample due to sequencing or mapping biases. Over the 32 call sets,
SURVIVOR had only 17 false positive calls for the simulated data. Genome STRiP performed best
with filtering out all falsely detected SVs, but suffers from the lowest ability to genotype SV
variations. STIX performed better as it can filter out 13 (76.47%) of the false positive SV calls. In
contrast, STIX also achieved a higher (71.76%) performance for correctly identifying SVs.
Although SVTyper had the highest accurately genotyped SVs it performed poorly by filtering out
81.82% of the false positives obtained during the discovery phase.
169
170   In summary, we observed that none of the methods is clearly superior for correctly genotyping
171   and correctly filtering/non-reporting variations. Strikingly, none of the program were able to
172   genotype insertions in the simulated data sets. Nevertheless, STIX and SV2 showed strong
173   performance, with a good balance of sensitivity and being able to correctly discard false
174   positives.
175

<u>Evaluation of SVs computational genotypers based on GiaB Ashkenazy Son</u>
We further assessed genotyping of SVs calls based on the long read DNA sequence data from
the Ashkenazy Son (HG002) reference sample. Specifically, we tested the currently released call
set (v0.5.0) from GiaB, generated using sequence resolved calls from multiple technologies such
as Illumina, PacBio, BioNano etc. and multiple SV callers and *de novo* assemblies based on these
technologies, alone or in combination [20]. It is important to note that 8,195 of these SV calls
could not be initially discovered with any Illumina assembly or caller but originated from PacBio
based calls or BioNano based calling.
We are using this call set to genotype the SVs based on a 300x Illumina bam file for HG002 and
compare the obtained SV genotype predictions to the genotypes reported by GiaB. The first
observation was that most of the SV genotypers were unable to process the VCF file provided
by GiaB. We used SURVIVOR to reduce the information included in the GiaB VCF file. Next, we
filtered out the reported INS and complex events from this call set as most SV genotypers
crashed while assessing these entries. Unfortunately, we were not able to run GenomeSTRiP
successfully as it kept crashing even on a subset of these calls.

191
192

193
194 *Figure 2: Evaluation based on GiaB call set v0.5.0 deletions only.*

195
Figure 2 displays the detectable deletions based on the GiaB call set (v0.5.0) per SV genotyper.
STIX performed the best among all methods identifying 24,574 (78.74%) of the provided
deletions. It is important to note that STIX does not currently report genotypes. Thus, we relied
only on the information if STIX found reads that support this event rather than genotype
information. DELLY performed as the second best identifying 18,528 (59.37%) deletions
followed by SVTyper (34.24%) and SV2 (9.99%). Only 6.27% of the deletion calls from GiaB call
set were genotyped by all SV genotype methods. Although this is a very low percent, it is
positive that up to 78.74% of the deletions could be successfully identified out of 62,676
deletions (20bp+) in total. Noteworthy, 4921 deletions out of this set were never observed by
any Illumina based caller or assembly. This highlights the potential benefit of using SV
genotypers.
207
Next, we assessed the size regimes that SVs genotypers were able to recognize SVs. The
deletions from GiaB call set 0.5.0 ranged from 20bp up to 997kbp with a median size of 36bp.
All of the SV genotypers were able to identify deletions down to a size of 20bp. Interestingly we
observed different median sizes of genotyped deletions, which represents the ability of specific
methods to genotype small or large events. DELLY (31bp) had the lowest median SV size
followed by SVTyper (32bp), STIX (35bp) and SV2 (116bp). Furthermore, DELLY (816kbp)

genotyped also the longest SVs followed by STIX (694kbp), SV2 (656bkbp) and SVTyper
(656bkbp).
216
217   When assessing the genotype concordance, DELLY performed the best with an agreement rate
218   of 87.08% given that it identified the variant in the first place. SV2 achieved a 78.59% of
219   genotype agreement, however it had one of the lowest recall rates (9.99%). SVTyper showed a
220   67.79% genotypes concordance. We did not evaluate STIX in this perspective since it does not
221   report a genotype estimation in its current version.
222
223   In summary, STIX and DELLY performed the best in re-identifying the deletions reported by GiaB
224   for HG0002. Furthermore, DELLY (87.08%) had also the highest agreement over the genotypes
225   with the GiaB call set.
226

Discussion

228   In this paper, we assessed the current state of SV genotyping methods. These methods are
229   essential not just in assigning genotypes to discovery methods, but represents the ability to
230   genotype already known, validated and functional annotated SVs. This latter aspect is
231   important for clinical applications as it represents an early opportunity to reliably assess
232   relevant SVs in the clinic.
233
Unfortunately, we discovered that many SV genotypers are only designed for their de novo SV
caller counterpart in mind to report genotype estimations. This is especially obvious for DELLY,
which can genotype all types subsequent to its discovery method, but only works on deletions
based on a standardized VCF file. The same behavior, although reduced, can be observed by
SVTyper that relies on specific IDs associated to translocations (in this case BND) events
provided by Lumpy.
240
We were able to establish the first assessments of sensitivity and false discovery rate for SV
genotypers not only focusing on Illumina detectable SVs, but further for SVs that were
impossible to be discovered by Illumina alone. The latter becomes important as the field is
continuously identifying SVs that based on long read technologies such as PacBio or Oxford
Nanopore [13, 15]. These technologies often enable the detection of more complex SVs and
also the detection of variations in regions that are hard to assess by Illumina alone. Thus, we
rely on SV genotyper to assess if a particular SVs is present either in experiments with large
sample sizes to evaluate the allele frequency or in clinical screenings to ease the diagnosis of
patients [16].
250
Unfortunately, our study also highlights multiple general issues of SV genotyping methods.
First, we observed that the methods tested here suffer from a limitation of SV types that they
are able to assess. None of the methods were able to assess novel insertions that also
represent repeat expansions, which is a subclass of SVs recognized to for their impact in cancer
and other phenotypes. Second, most of the methods suffer from a very strict VCF formatting

requirement ignoring the current standard and relied further on individual flags that are hard or
impossible to regenerate.
258
Overall STIX performed well on simulated and GiaB based SVs calls. It showed a good balance of
sensitivity vs false discovery and was able to be run on standard VCF files. Nevertheless, the
lack of genotype estimations is a clear limitation since it is often relevant to know if a variation
is heterozygous or homozygous. Overall, the current methods, although limited in performance,
represents an advantage to diagnose patients with SVs compared to the discovery of SVs simply
because of their much reduced false discovery rate.
265
Potential implications
SVs genotyping represents a possibility to infer SVs in clinical diagnosis by solving the problems
of false discovery and false negative called SVs, compared to the discovery SV methods.
However, genotyping SVs methods seem to require additional development to improve their
ability to operate on different size regimes and all types of SVs (including insertions). Here we
presented an overview of the current state-of-the-art methods, which highlights the need to
improve upon the current state of the art to enable SV diagnosis of patients in clinical setups.
273
Methods
Simulated datasets
We simulated 20 SVs per dataset each for a certain type (indel, inversions, duplication and
translocation) and a certain size (100bp, 250bp, 500bp, 1kbp, 2kbp, 5kbp, 10kbp, 50kbp) for chr
21 and 22 using SURVIVOR simSV. These simulations included a 1% SNP rate. After the
simulation of the sample genomes we simulated reads using Mason [31] with the following
parameter "Illumina -Il 500 -n 100 –N 39773784 -sq -mp -rn 2 " to generate 100bp paired-end
Illumina like reads. The reads were mapped with BWA MEM[32] using the –M option to mark
duplicated reads to the entire genome (GRCh38-2.1.0). Subsequently, we ran Manta (v1.2.1),
DELLY (v0.7.8) and Lumpy (v0.2.13) to call SVs over the simulated datasets. For each data set
we generated a union call set based on all 3 callers using SURVIVOR merge (v1.0.3) allowing
1kbp distance and allowing only the same SV type to be merged. This union set, as well as the
SV genotyper output, was evaluated with SURVIVOR eval for the following categories:
Precise: calling an SVs within 10bp and inferring the correct type. Indicated: allowing a
maximum of 1kbp between the simulated and the called breakpoints and ignoring the
predicted type of SVs. Missing: a simulated SVs but not re identified. Additional: a SVs that was
called, but not simulated. The results were summarized using a costume R script operating on
the output of SURVIVOR available on request.
292
SV genotyping: simulated data
For genotyping the simulated data set we used the union call VCF based on the SURVIVOR
output as described above. We used DELLY (v0.7.8) specifying the output (-o), the vcf to be
genotyped (-v) and the reference file (-g) as fasta and the bam file. We ran DELLY with the VCF
file from SURVIVOR over the SV discovery caller. The obtained output from DELLY was
converted using bcftools view (v1.7 (using htslib 1.7)) [26] to obtain a VCF file and was filtered

to ignore genotyped calls with 0/0. SVTyper (v0.1.4) was used on the VCF generated from
SURVIVOR based on the discovery phase. We filtered the obtained VCF for genotypes that could
not have been accessed by SVTyper. SV2 (version 1.4.3) was run on the SURVIVOR generated
VCF file for SVs genotyping but required also a SNV file. We generated this SNV file using
Freebayes (v1.1.0-46-g8d2b3a0-dirty) [33] with the default parameters. The resulting SNV file
from Freebayes was compressed and indexed by bgzip and tabix –p vcf [34], respectively. SV2
report their result in three folders (sv2_preprocessed, sv2_features and sv2_genotypes) from
which we used the result reported in sv2_genotypes to benchmark the method. Genome
STRIP(v2.00.1774) was used following the suggested parameters and the VCF file generated by
SURVIVOR. STIX (early version available over GitHub on April 6th 2018) was used to index the
bam file using giggle (v0.6.3) [27], excord (v0.2.2) and samtools (v1.7) [26] following the
suggested pipeline. Next, we run STIX with "-s 500" on the VCF files from SURVIVOR and
ignoring output VCF entries with "STIX_ZERO=1", which filters out entries where STIX does not
find any evidence for the SV.
313
SV genotyping: GiaB
We obtained the GiaB SV call set (v0.5.0) from ftp://ftp-
trace.ncbi.nlm.nih.gov/giab/ftp/data/AshkenazimTrio/analysis/NIST_UnionSVs_12122017/ .
The SNV calls were taken from here ftp://ftp-
trace.ncbi.nlm.nih.gov/giab/ftp/release/AshkenazimTrio/HG002_NA24385_son/latest/GRCh37/
and the corresponding bam file from ftp://ftp-
trace.ncbi.nlm.nih.gov/giab/ftp/data/AshkenazimTrio/HG002_NA24385_son/NIST_HiSeq_HG00
2_Homogeneity10953946/NHGRI_Illumina300X_AJtrio_novoalign_bams/HG002.hs37d5.300x.b
am . The SVs call set needed to be filtered and reduced for just one sample (HG002) using cat
and SURVIVOR and was subsequently filtered for deletions only. We ran all SV genotyping
methods like described above. Subsequently,we filtered the results for genotypes: 0/1 and 1/1
with the exception of STIX. STIX was filtered base on if it reports reads to support the SVs or
not. This was necessary since STIX does currently not report genotypes. After filtering we
merged all data sets together including the original VCF provided using SURVIVOR with a
maximum distance of 10bp and requiring the same types. We analyzed these merged calls
based on if the original call set reported a genotype to be heterozygous or homozygous
alternative. The Venn diagram was generated based on the support vector reported by
SURVIVOR and the R package Venn.diagram. The length of the SVs that were able to be
genotyped were extracted using awk filtering for existing calls.
333
Availability of data and materials
The data sets used in this study are available here ftp://ftp-
trace.ncbi.nlm.nih.gov/giab/ftp/data/AshkenazimTrio/analysis/NIST_UnionSVs_12122017/ and
from ftp://ftp-
trace.ncbi.nlm.nih.gov/giab/ftp/data/AshkenazimTrio/HG002_NA24385_son/NIST_HiSeq_HG00
2_Homogeneity10953946/NHGRI_Illumina300X_AJtrio_novoalign_bams/HG002.hs37d5.300x.b
am. The simulated data sets are available on request.
341

Declarations

Funding
This research was supported by National Institutes of Health award (UM1 HG008898).

Authors' contributions
VC and FS performed the analysis. VC, FS and RG wrote the manuscript. FS and RG directed the project.

Ethics approval and consent to participate
Not applicable

Consent for publication
Not applicable

Competing interests
F.J.S. has participated in PacBio sponsored meetings over the past few years and have received travel reimbursement and honoraria for presenting at these events

References
1. Weischenfeldt J, Symmons O, Spitz F and Korbel JO. Phenotypic impact of genomic structural variation: insights from and for human disease. Nat Rev Genet. 2013;14 2:125-38. doi:10.1038/nrg3373.
2. Lupski JR. Structural variation mutagenesis of the human genome: Impact on disease and evolution. Environ Mol Mutagen. 2015;56 5:419-36. doi:10.1002/em.21943.
3. Macintyre G, Ylstra B and Brenton JD. Sequencing Structural Variants in Cancer for Precision Therapeutics. Trends Genet. 2016;32 9:530-42. doi:10.1016/j.tig.2016.07.002.
4. Consortium GT, Laboratory DA, Coordinating Center -Analysis Working G, Statistical Methods groups-Analysis Working G, Enhancing Gg, Fund NIHC, et al. Genetic effects on gene expression across human tissues. Nature. 2017;550 7675:204-13. doi:10.1038/nature24277.
5. Jeffares DC, Jolly C, Hoti M, Speed D, Shaw L, Rallis C, et al. Transient structural variations have strong effects on quantitative traits and reproductive isolation in fission yeast. Nat Commun. 2017;8:14061. doi:10.1038/ncomms14061.
6. Sebat J, Lakshmi B, Troge J, Alexander J, Young J, Lundin P, et al. Large-scale copy number polymorphism in the human genome. Science. 2004;305 5683:525-8. doi:10.1126/science.1098918.
7. Sudmant PH, Rausch T, Gardner EJ, Handsaker RE, Abyzov A, Huddleston J, et al. An integrated map of structural variation in 2,504 human genomes. Nature. 2015;526 7571:75-81. doi:10.1038/nature15394.

8.   Tattini L, D'Aurizio R and Magi A. Detection of Genomic Structural Variants from Next-
Generation Sequencing Data. Front Bioeng Biotechnol. 2015;3:92.
doi:10.3389/fbioe.2015.00092.
9.   Alkan C, Coe BP and Eichler EE. Genome structural variation discovery and genotyping.
Nat Rev Genet. 2011;12 5:363-76. doi:10.1038/nrg2958.
10.   English AC, Salerno WJ and Reid JG. PBHoney: identifying genomic variants via long-read
discordance and interrupted mapping. BMC Bioinformatics. 2014;15:180.
doi:10.1186/1471-2105-15-180.
11.   Mills RE, Walter K, Stewart C, Handsaker RE, Chen K, Alkan C, et al. Mapping copy
number variation by population-scale genome sequencing. Nature. 2011;470 7332:59-
65. doi:10.1038/nature09708.
12.   Teo SM, Pawitan Y, Ku CS, Chia KS and Salim A. Statistical challenges associated with
detecting copy number variations with next-generation sequencing. Bioinformatics.
2012;28 21:2711-8. doi:10.1093/bioinformatics/bts535.
13.   Sedlazeck FJ, Rescheneder P, Smolka M, Fang H, Nattestad M, von Haeseler A, et al.
Accurate detection of complex structural variations using single-molecule sequencing.
Nat Methods. 2018; doi:10.1038/s41592-018-0001-7.
14.   Goodwin S, McPherson JD and McCombie WR. Coming of age: ten years of next-
generation sequencing technologies. Nat Rev Genet. 2016;17 6:333-51.
doi:10.1038/nrg.2016.49.
15.   Chaisson MJ, Huddleston J, Dennis MY, Sudmant PH, Malig M, Hormozdiari F, et al.
Resolving the complexity of the human genome using single-molecule sequencing.
Nature. 2015;517 7536:608-11. doi:10.1038/nature13907.
16.   Merker JD, Wenger AM, Sneddon T, Grove M, Zappala Z, Fresard L, et al. Long-read
genome sequencing identifies causal structural variation in a Mendelian disease. Genet
Med. 2018;20 1:159-63. doi:10.1038/gim.2017.86.
17.   Pedersen BS, Layer RM and Quinlan AR. Vcfanno: fast, flexible annotation of genetic
variants. Genome Biol. 2016;17 1:118. doi:10.1186/s13059-016-0973-5.
18.   Sedlazeck FJ, Dhroso A, Bodian DL, Paschall J, Hermes F and Zook JM. Tools for
annotation and comparison of structural variation. F1000Res. 2017;6:1795.
doi:10.12688/f1000research.12516.1.
19.   Lappalainen I, Lopez J, Skipper L, Hefferon T, Spalding JD, Garner J, et al. DbVar and
DGVa: public archives for genomic structural variation. Nucleic Acids Res. 2013;41
Database issue:D936-41. doi:10.1093/nar/gks1213.
20.   Zook JM, Catoe D, McDaniel J, Vang L, Spies N, Sidow A, et al. Extensive sequencing of
seven human genomes to characterize benchmark reference materials. Sci Data.
2016;3:160025. doi:10.1038/sdata.2016.25.
21.   Rausch T, Zichner T, Schlattl A, Stutz AM, Benes V and Korbel JO. DELLY: structural
variant discovery by integrated paired-end and split-read analysis. Bioinformatics.
2012;28 18:i333-i9. doi:10.1093/bioinformatics/bts378.
22.   Handsaker RE, Van Doren V, Berman JR, Genovese G, Kashin S, Boettger LM, et al. Large
multiallelic copy number variations in humans. Nat Genet. 2015;47 3:296-303.
doi:10.1038/ng.3200.
23.   Layer RM: https://github.com/ryanlayer/stix (2018).

24.   Antaki D, Brandler WM and Sebat J. SV2: accurate structural variation genotyping and
427   de novo mutation detection from whole genomes. Bioinformatics. 2018;34 10:1774-7.
428   doi:10.1093/bioinformatics/btx813.

429   25.   Chiang C, Layer RM, Faust GG, Lindberg MR, Rose DB, Garrison EP, et al. SpeedSeq:
430   ultra-fast personal genome analysis and interpretation. Nat Methods. 2015;12 10:966-8.
431   doi:10.1038/nmeth.3505.

432   26.   Li H. A statistical framework for SNP calling, mutation discovery, association mapping
433   and population genetical parameter estimation from sequencing data. Bioinformatics.
434   2011;27 21:2987-93. doi:10.1093/bioinformatics/btr509.

435   27.   Layer RM, Pedersen BS, DiSera T, Marth GT, Gertz J and Quinlan AR. GIGGLE: a search
436   engine for large-scale integrated genome analysis. Nat Methods. 2018;15 2:123-6.
437   doi:10.1038/nmeth.4556.

438   28.   McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The
439   Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA
440   sequencing data. Genome Res. 2010;20 9:1297-303. doi:10.1101/gr.107524.110.

441   29.   Layer RM, Chiang C, Quinlan AR and Hall IM. LUMPY: a probabilistic framework for
442   structural variant discovery. Genome Biol. 2014;15 6:R84. doi:10.1186/gb-2014-15-6-
443   r84.

444   30.   Chen X, Schulz-Trieglaff O, Shaw R, Barnes B, Schlesinger F, Kallberg M, et al. Manta:
445   rapid detection of structural variants and indels for germline and cancer sequencing
446   applications. Bioinformatics. 2016;32 8:1220-2. doi:10.1093/bioinformatics/btv710.

447   31.   Holtgrewe M. *Mason-A Read Simulator for Second Generation Sequencing Data*. 2010.
448   Institut für Mathematik und Informatik, Freie Universität Berlin.

449   32.   Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM.
450   ArXiv e-prints. 2013; doi: arXiv:1303.3997 [q-bio.GN].

451   33.   Garrison E and Marth G. Haplotype-based variant detection from short-read sequencing.
452   ArXiv e-prints. 2012.

453   34.   Li H. Tabix: fast retrieval of sequence features from generic TAB-delimited files.
454   Bioinformatics. 2011;27 5:718-9. doi:10.1093/bioinformatics/btq671.